Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel

Drug Development and Industrial Pharmacy

Volumn 36, Issue 11, 2010, Pages 1377-1387

  Kollipara, Sivacharan ^a   Bende, Girish ^a   Movva, Snehalatha ^a   Saha, Ranendra ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Central composite design; Optimization; Paclitaxel; PLGA nanoparticles; Response surface methodology

Indexed keywords

MIGLYOL; NANOPARTICLE; PACLITAXEL; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; EMULSION; GASTROINTESTINAL ABSORPTION; MALE; NONHUMAN; PARTICLE SIZE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; EMULSIONS; INTESTINAL ABSORPTION; LACTIC ACID; MALE; MODELS, THEORETICAL; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; SOLVENTS; TRIGLYCERIDES; ULTRASONICS;

EID: 77956934839     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.487263     Document Type: Article

References (46)

1. Inbar M, Merimsky O, Chaitchik S. (1997). Taxanes: A breakthrough in cancer chemotherapy. Harefuah, 133(1-2):31-36
2. Schiff PB, Fant J, Horwitz SB. (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277:665-667
3. Schiff PB, Horwitz SB. (1981). Taxol stabilizes microtubules in mouse fibroblast cells. Biochemistry, 20:3247-3252
4. Haldar S, Chintapalli J, Croce CM. (1996). Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res, 56:1253-1255
5. Spencer CM, Faulds D. (1994). Paclitaxel-a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48(5):794-847.
6. Ishitobi M, Shin E, Kikkawa N. (2001). Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int J Clin Oncol, 6(1):55-58
7. Thigpen JT. (2000). Chemotherapy for advanced ovarian cancer: Overview of randomized trials. Semin Oncol, 27(3):11-16
8. Chang AY, Rubins J, Asbury R, Boros L, Hui LF. (2001). Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol, 28(4):10-13
9. Li KW, Dang W, Tyler BM, Troiano G, Thian T, Brem H, et al. (2003). Polilactofate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Anticancer Res, 15(9):3441-3447
10. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Sprub T, et al. (2002). Transport of paclitaxel (Taxol) across the bloodbrain barrier in vitro and in vivo. J Clin Invest, 10(9):1309-1317
11. Rowinsky EK, Cazenave LA, Donehower RC. (1990). Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst, 82:1247-1259
12. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, et al. (2005). Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmcol, 45:674-682
13. Gallo JM, Li S, Guo P, Redd K, Ma J. (2003). The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res, 63:5114-5117
14. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, et al. (2003). Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res, 9:2849-2855
15. Weiss R, Donehower RC, Wiernik PH. (1990). Hypersensitivity reactions from taxol. J Clin Oncol, 8:1263-1268
16. Friedland D, Gorman G, Treat J. (1993). Hypersensitivity reactions from taxol and etoposide. J Natl Cancer Inst, 85(24):2036.
17. Gregory R, DeLisa AF. (1993). Paclitaxel: A new antineoplastic agent for refractory ovarian cancer. Clin Pharm, 42:401-415 (Pubitemid 23149973)
18. Fjallskog ML, Frii L, Bergh J. (1993). Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet, 342(8875):873.
19. Singla AK, Garg A, Aggarwal D. (2002). Paclitaxel and its formulations. Int J Pharm, 235:179-192
20. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, et al. (2005). Multicenter phase II trial of ABI-007, an albuminbound paclitaxel, in women with metastatic breast cancer. J Clin Oncol, 23(25):6019-6026
21. Sharma A, Straubinger RM. (1994). Novel Taxol formulations: Preparation and characterization of Taxol-containing liposomes. Pharm Res, 11:889-895
22. Gupte A, Ciftci K. (2004). Formulation and characterization of paclitaxel, 5-FU and paclitaxel + 5-FU microspheres. Int J Pharm, 276(1-2):93-106.
23. Liggins RT, Cruz T, Min W, Liang L, Hunter WL, Burt HM. (2004). Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: Biocompatibility and efficacy determinations in rabbits. Inflamm Res, 53(8):363-372
24. Lundberg BB. (1997). A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol, 49(1):16-21.
25. Tarr BD, Sambandan TG, Yalkowsky SH. (1987). A new parenteral emulsion for the administration of Taxol. Pharm Res, 4(2):162-165
26. Yegin BA, Benot JP, Lamprecht A. (2006). Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev Ind Pharm, 32(9):1089-1094
27. Si-Shen F, Li M, Win KY, Guofeng H. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem, 11(4):413-424
28. Yang S, Gursoy RN, Lambert G, Benita S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of p-glycoprotein inhibitors. Pharm Res, 21(2):261-270
29. Wang J, Mongayt D, Torchilin VP. (2005). Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target, 13(1):73-80. (Pubitemid 40309464)
30. Couvreur P, Kante B, Lenaerts V, Scailteur V, Ronald M, Speiser P. (1980). Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci, 69(2):199-202.
31. Peppas LB, Blanchette JO. (2004). Nanoparticles and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56:1649-1659
32. Bennis S, Chapey C, Couvreur P, Robert J. (1994). Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacryate nanospheres against multidrug-resistant cells in culture. Eur J Cancer, 30A(1):89-93.
33. Guerrero DQ, Allemann E, Fessi H, Doelker E. (1998). Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm, 24(12):1113-1128
34. Agnihotri SA, Aminabhavi TM. (2007). Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm, 33(11):1254-1262
35. Graves RA, Poole D, Moiseyev R, Bostanian LA, Mandal TK. (2008). Encapsulation of indomethacin using coaxial ultrasonic atomization followed by solvent evaporation. Drug Dev Ind Pharm, 34(4):419-426
36. Attivi D, Wehrle P, Ubrich N, Damge C, Hoffman M, Maincent P. (2005). Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug Dev Ind Pharm, 31(2):179-189
37. Shi K, Cui F. (2009). Optimized formulation of high-pay load PLGA nanoparticles containing insulin-lauryl sulfate complex. Drug Dev Ind Pharm, 35(2):177-184
38. Akhnazarova S, Kafaro V. (1982). Experiment optimization in chemistry and chemical engineering. Moscow: Mir House Publications.
39. Bolton S. (1997). Pharmaceutical statistics: Practical and clinical applications. New York: Marcel Dekker.
40. Levy MY, Benita S. (1990). Drug release from submicronized o/ w emulsion: A new in vitro kinetic evaluation model. Int J Pharm, 66(1-3):29-37.
41. Barzegar-Jalali M, Adibkia K, Valizadeh H, Shadbad MRS, Nokhodchi A, Omidi Y, et al. (2008). Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci, 11(1):167-177
42. Doluisio JT, Bilups NF, Tukker JJ, Crommelin DJA. (1969). Drug absorption I: An in-situ rat gut technique yielding realistic absorption rates. J Pharm Sci, 58:1197-1198
43. Schurgers N, Bijdendijk J, Tukker JJ, Crommelin DJA. (1986). Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ. J Pharm Sci, 75(2):117-119
44. Singh AT, Jaggi M, Khattar D, Awasthi A, Mishra SK, Tyagi S, et al. (2008). A novel nanopolymer based tumor targeted delivery system for paclitaxel. J Clin Oncol, 26(15S):11095.
45. Niu F, Roby KF, Rajewski RA, Decedue C, Subramaniam B. (2006). Polymeric drug delivery II: Polymeric matrices and drug particle engineering. Washington, DC: ACS Publications.
46. Jani P, Halbert GW, Langridge J, Florence AT. (1990). Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol, 42(12):821-826